Taiwan · Delayed Price · Currency is TWD Obigen Pharma Statistics
Total Valuation
Obigen Pharma has a market cap or net worth of TWD 3.94 billion. The enterprise value is 3.51 billion.
| Market Cap | 3.94B |
| Enterprise Value | 3.51B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Obigen Pharma has 106.92 million shares outstanding. The number of shares has increased by 0.22% in one year.
| Current Share Class | 106.92M |
| Shares Outstanding | 106.92M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | n/a |
| Float | 53.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.85 |
| P/TBV Ratio | 5.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.76 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.09 |
Financial Position
The company has a current ratio of 18.30, with a Debt / Equity ratio of 0.06.
| Current Ratio | 18.30 |
| Quick Ratio | 17.21 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.33 |
| Interest Coverage | -197.10 |
Financial Efficiency
Return on equity (ROE) is -21.32% and return on invested capital (ROIC) is -13.13%.
| Return on Equity (ROE) | -21.32% |
| Return on Assets (ROA) | -12.96% |
| Return on Invested Capital (ROIC) | -13.13% |
| Return on Capital Employed (ROCE) | -23.45% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -5.43M |
| Employee Count | 60 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 37.29 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 46.34 |
| Average Volume (20 Days) | 141,033 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -339.80M |
| Pretax Income | -325.96M |
| Net Income | -325.96M |
| EBITDA | -240.53M |
| EBIT | -339.80M |
| Earnings Per Share (EPS) | -3.07 |
Balance Sheet
The company has 514.37 million in cash and 81.16 million in debt, with a net cash position of 433.21 million or 4.05 per share.
| Cash & Cash Equivalents | 514.37M |
| Total Debt | 81.16M |
| Net Cash | 433.21M |
| Net Cash Per Share | 4.05 |
| Equity (Book Value) | 1.38B |
| Book Value Per Share | 12.92 |
| Working Capital | 602.46M |
Cash Flow
In the last 12 months, operating cash flow was -243.26 million and capital expenditures -5.71 million, giving a free cash flow of -248.98 million.
| Operating Cash Flow | -243.26M |
| Capital Expenditures | -5.71M |
| Depreciation & Amortization | 99.27M |
| Net Borrowing | -14.80M |
| Free Cash Flow | -248.98M |
| FCF Per Share | -2.33 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Obigen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.22% |
| Shareholder Yield | -0.22% |
| Earnings Yield | -8.27% |
| FCF Yield | -6.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |